LES negativo para anticorpos antifosfolípides (APL) |
DIU com cobre (A)2929 Sanchez-Guerrero J, Uribe AG, Jiménez-Santana L, Mestanza-Peralta M, Lara-Reyes P, Seuc AH, et al. A trial of contraceptive methods in women with systemic lupus erythematosus. N Engl J Med. 2005;353:2539-49.,3131 Culwell KR, Curtis KM, del Carmen Cravioto M. Safety of contraceptive method use among women with systemic lupus erythematosus: a systematic review. Obstet Gynecol. 2009;114:341-53. DIU liberador de levonorgestrel (C)1818 WHO. Medical eligibility criteria for contraceptive use. 5th ed. Geneva: WHO; 2015. Available from: http://www.who.int/reproductivehealth/publications/family_planning/Ex-Summ-MEC-5/en/. http://www.who.int/reproductivehealth/pu...
,3838 Mc Nicholas C, Peipert JF. Long-acting reversible contraception for adolescents. Curr Opin Obstet Gynecol. 2012;24:293-8.
|
Contraceptivo oral combinado ou pílulas com apenas progestina para doença estável com atividade leve (A)2828 Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med. 2005;353:2550-8.,2929 Sanchez-Guerrero J, Uribe AG, Jiménez-Santana L, Mestanza-Peralta M, Lara-Reyes P, Seuc AH, et al. A trial of contraceptive methods in women with systemic lupus erythematosus. N Engl J Med. 2005;353:2539-49.,3131 Culwell KR, Curtis KM, del Carmen Cravioto M. Safety of contraceptive method use among women with systemic lupus erythematosus: a systematic review. Obstet Gynecol. 2009;114:341-53. ou DMPA (C)1313 Silva CA, Hilario MO, Febronio MV, Oliveira SK, Almeida RG, Fonseca AR, et al. Pregnancy outcome in juvenile systemic lupus erythematosus: a Brazilian multicenter cohort study. J Rheumatol. 2008;35:1414-8.
|
Nos “acidentes contraceptivos” em risco de gravidez (falha no uso), indica-se a contracepção de emergência (NS) |
LES positivo (ou desconhecido) para APL/síndrome antifosfolipídica |
DIU com cobre (NS) ou DIU liberador de levonorgestrel (C)1818 WHO. Medical eligibility criteria for contraceptive use. 5th ed. Geneva: WHO; 2015. Available from: http://www.who.int/reproductivehealth/publications/family_planning/Ex-Summ-MEC-5/en/. http://www.who.int/reproductivehealth/pu...
|
Pílulas com apenas progestágeno (B)3131 Culwell KR, Curtis KM, del Carmen Cravioto M. Safety of contraceptive method use among women with systemic lupus erythematosus: a systematic review. Obstet Gynecol. 2009;114:341-53.,4646 Mantha S, Karp R, Raghavan V, Terrin N, Bauer A, Zwicker JI. Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis. BMJ. 2012;345:e4944. ou DMPA4848 Yamakami L, Serafini P, de Araujo D, Bonfá E, Leon E, Baracat E, et al. Ovarian reserve in women with primary antiphospholipid syndrome. Lupus. 2014;23:862-7.,4949 Yamakami LY, de Araujo DB, Silva CA, Baracat EC, de Carvalho JF. Severe hemorrhagic corpus luteum complicating anticoagulation in antiphospholipid syndrome. Lupus. 2011;20:523-6.
|
LES com trombocitopenia grave |
DIU liberador de levonorgestrel (C)1818 WHO. Medical eligibility criteria for contraceptive use. 5th ed. Geneva: WHO; 2015. Available from: http://www.who.int/reproductivehealth/publications/family_planning/Ex-Summ-MEC-5/en/. http://www.who.int/reproductivehealth/pu...
|
Contraceptivo oral combinado para a doença leve de atividade estável (NS) |
Outras doenças (artrite idiopática juvenil, dermatomiosite juvenil) |
Contraceptivo oral combinado ou outro contraceptivo hormonal combinado (NS) |
Contraceptivo reversível de ação prolongada (inclui DIU ou implante) (NS) |
Nos “acidentes contraceptivos” em risco de gravidez (falha no uso), indica-se a contracepção de emergência (NS) |